Michael Degregorio

Title(s)Professor Emeritus, MED: Int Med Hematology/Oncology
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Complexity of Translating Analytics to Recent Cannabis Use and Impairment. J AOAC Int. 2024 May 02; 107(3):493-505. DeGregorio MW, Kao CJ, Wurz GT. PMID: 38410076.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsPHPublic Health
    2. Examining impairment and kinetic patterns associated with recent use of hemp-derived Δ8-tetrahydrocannabinol: case studies. J Cannabis Res. 2022 Jul 07; 4(1):36. Wurz GT, Montoya E, DeGregorio MW. PMID: 35799289; PMCID: PMC9261056.
      View in: PubMed   Mentions: 4  
    3. Indeterminacy of cannabis impairment and ∆9-tetrahydrocannabinol (∆9-THC) levels in blood and breath. Sci Rep. 2022 05 18; 12(1):8323. Wurz GT, DeGregorio MW. PMID: 35585089; PMCID: PMC9117256.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    4. Lumbopelvic postural differences in adolescent idiopathic scoliosis: A pilot study. Gait Posture. 2022 03; 93:73-77. Jamison M, Glover M, Peterson K, DeGregorio M, King K, Danelson K, O'Gara T. PMID: 35093665.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. A comprehensive breath test that confirms recent use of inhaled cannabis within the impairment window. Sci Rep. 2021 11 23; 11(1):22776. DeGregorio MW, Wurz GT, Montoya E, Kao CJ. PMID: 34815467; PMCID: PMC8611040.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsPHPublic Health
    6. Development and Validation of a Liquid Chromatography High-Resolution Mass Spectrometry (LC-HRMS) Bioanalytical Method for Quantifying Cannabinoids in Whole Blood: Application for Determining Recent Cannabis Use. J AOAC Int. 2020 Jun 01; 103(3):725-735. DeGregorio MW, Audino SA, Montoya E, Phong A, Kao CJ, Wurz GT. PMID: 33241370.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    7. Repurposing ospemifene for potentiating an antigen-specific immune response. Menopause. 2017 04; 24(4):437-451. Kao CJ, Wurz GT, Lin YC, Vang DP, Phong B, DeGregorio MW. PMID: 27922937; PMCID: PMC5365365.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    8. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol. 2016 Jan; 8(1):4-31. Wurz GT, Kao CJ, DeGregorio MW. PMID: 26753003; PMCID: PMC4699263.
      View in: PubMed   Mentions: 26  
    9. Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice. Cancer Immunol Res. 2015 Jul; 3(7):741-50. Kao CJ, Wurz GT, Lin YC, Vang DP, Griffey SM, Wolf M, DeGregorio MW. PMID: 25672395.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    10. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clin Interv Aging. 2014; 9:1939-50. Wurz GT, Kao CJ, DeGregorio MW. PMID: 25419123; PMCID: PMC4235480.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    11. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids. 2014 Nov; 90:82-93. DeGregorio MW, Zerbe RL, Wurz GT. PMID: 25087944.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    12. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis. 2014 Jun; 6(6):571-3. DeGregorio M, Soe L, Wolf M. PMID: 24976972; PMCID: PMC4073360.
      View in: PubMed   Mentions: 5  
    13. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model. Cancer Immunol Res. 2014 Jun; 2(6):581-9. Kao CJ, Wurz GT, Monjazeb AM, Vang DP, Cadman TB, Griffey SM, Wolf M, DeGregorio MW. PMID: 24894093.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    14. Response to: "Deceptive argumentation against diagnostic microdosing of anticancer drugs" by Dirk Theile and Gerd Mikus (Letter dated February 13, 2014). Int J Cancer. 2014 Oct 01; 135(7):1751-2. Wurz GT, DeGregorio MW. PMID: 24615713.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: implications for diagnostic microdosing. Int J Cancer. 2015 Apr 01; 136(7):1485-93. Wurz GT, DeGregorio MW. PMID: 24510760.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    16. Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother. 2014; 10(11):3383-93. Wurz GT, Kao CJ, Wolf M, DeGregorio MW. PMID: 25483673; PMCID: PMC4514140.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    17. Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development. J Vis Exp. 2013 Oct 30; (80):e50868. Vang DP, Wurz GT, Griffey SM, Kao CJ, Gutierrez AM, Hanson GK, Wolf M, DeGregorio MW. PMID: 24300078; PMCID: PMC3965342.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    18. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womens Health. 2013 Sep 25; 5:605-11. Soe LH, Wurz GT, Kao CJ, Degregorio MW. PMID: 24109197; PMCID: PMC3792833.
      View in: PubMed   Mentions: 7  
    19. Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy. Oncoimmunology. 2013 Oct 01; 2(10):e26285. Kao CJ, Wurz GT, Schröder A, Wolf M, Degregorio MW. PMID: 24498545; PMCID: PMC3896473.
      View in: PubMed   Mentions: 5     Fields:    
    20. Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model. J Transl Med. 2013 Mar 13; 11:64. Wurz GT, Gutierrez AM, Greenberg BE, Vang DP, Griffey SM, Kao CJ, Wolf M, DeGregorio MW. PMID: 23496860; PMCID: PMC3605365.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    21. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas. 2013 Mar; 74(3):220-5. Wurz GT, Soe LH, DeGregorio MW. PMID: 23332519.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    22. L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible? Oncoimmunology. 2012 Nov 01; 1(8):1422-1424. Degregorio M, Degregorio M, Wurz GT, Wurz GT, Gutierrez A, Gutierrez A, Wolf M. PMID: 23243615; PMCID: PMC3518524.
      View in: PubMed   Mentions: 6     Fields:    
    23. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin Cancer Res. 2012 May 15; 18(10):2861-71. Mehta NR, Wurz GT, Burich RA, Greenberg BE, Griffey S, Gutierrez A, Bell KE, McCall JL, Wolf M, DeGregorio M. PMID: 22434666.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    24. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012 Jan; 19(1):96-103. Burich RA, Mehta NR, Wurz GT, McCall JL, Greenberg BE, Bell KE, Griffey SM, DeGregorio MW. PMID: 21926925; PMCID: PMC3246110.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    25. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. 2010 Jun; 6(6):773-9. McCall JL, DeGregorio MW. PMID: 20429673.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    26. Pharmacologic effects of ospemifene in rhesus macaques: a pilot study. Basic Clin Pharmacol Toxicol. 2008 Jun; 102(6):552-8. Wurz GT, Hellmann-Blumberg U, DeGregorio MW. PMID: 18346046.
      View in: PubMed   Mentions: 7     Fields:    Translation:Animals
    27. Ineffectiveness of American ginseng in the prevention of dimethylbenzanthracene-induced mammary tumors in mice. Oncol Res. 2006; 16(6):251-60. Wurz GT, Marchisano-Karpman C, DeGregorio MW. PMID: 17476970.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    28. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006; 24(4):314-8. Komi J, Lankinen KS, DeGregorio M, Heikkinen J, Saarikoski S, Tuppurainen M, Halonen K, Lammintausta R, Väänänen K, Ylikorkala O, Erkkola R. PMID: 16816926.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    29. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res. 2005; 7(6):R881-9. Namba R, Young LJ, Maglione JE, McGoldrick ET, Liu S, Wurz GT, DeGregorio MW, Borowsky AD, MacLeod CL, Cardiff RD, Gregg JP. PMID: 16280035; PMCID: PMC1410776.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimals
    30. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol. 2005 Nov; 97(3):230-40. Wurz GT, Read KC, Marchisano-Karpman C, Gregg JP, Beckett LA, Yu Q, Degregorio MW. PMID: 16153821.
      View in: PubMed   Mentions: 18     Fields:    Translation:Animals
    31. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother Pharmacol. 2006 Feb; 57(3):335-42. DeGregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW. PMID: 16047147.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    32. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause. 2005 Mar; 12(2):202-9. Komi J, Lankinen KS, Härkönen P, DeGregorio MW, Voipio S, Kivinen S, Tuimala R, Vihtamäki T, Vihko K, Ylikorkala O, Erkkola R. PMID: 15772568.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    33. "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis. 2005; 15(3):365-72. Paterniti DA, Melnikow J, Nuovo J, Henderson S, DeGregorio M, Kuppermann M, Nease R. PMID: 16108294.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    34. Arzoxifene Eli Lilly. IDrugs. 2003 Sep; 6(9):880-5. Marchisano-Karpman C, DeGregorio MW. PMID: 12964068.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    35. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003; 42(4):361-72. Morello KC, Wurz GT, DeGregorio MW. PMID: 12648026.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    36. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. PMID: 12643003.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    37. SERMs: current status and future trends. Crit Rev Oncol Hematol. 2002 Jul; 43(1):63-76. Morello KC, Wurz GT, DeGregorio MW. PMID: 12098608.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    38. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol. 2000 Sep; 56(6-7):469-75. DeGregorio MW, Wurz GT, Taras TL, Erkkola RU, Halonen KH, Huupponen RK. PMID: 11049009.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    39. Hormone replacement therapy and breast cancer: revisiting the issues. J Am Pharm Assoc (Wash). 1998 Nov-Dec; 38(6):738-44; quiz 744-6. DeGregorio MW, Taras TL. PMID: 9861792.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Michael's Networks
    Concepts (195)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California